Dropbox Inc vs Neurocrine Biosciences Inc — how do they compare? Dropbox Inc trades at $33.64 (market cap $7.52B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Dropbox Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DBX | NBIX | |
|---|---|---|
Market Cap | $7.52B | $16.76B |
Sector | Technology | Health |
52-Week High | $35.00 | $185.50 |
52-Week Low | $22.06 | $123.10 |
Enterprise Value | $10.38B | $16.78B |
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.81, up 0.78% today, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.75, exceeding estimates, and raised its full-year outlook. Revenue remains stable at $2.5B, with strong gross margins of 79.72%. However, negative shareholder equity and high debt levels pose financial risks.
The outlook is mixed: strong profitability and AI-driven growth support upside, but elevated leverage and competitive pressures warrant caution. Analyst sentiment is divided, with 37.5% recommending Buy. Key risks include execution challenges and market volatility. The stock's trajectory hinges on sustaining core business momentum amid macroeconomic headwinds.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
Latest headlines on both assets
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →